

GISEA/OEG

International Symposium 2025

PRECISION MEDICINE
VS PERSONALIZED MEDICINE:
HOW TO MANAGE THE COMPLEXITY
OF RHEUMATIC DISEASES

MILAN
21st/23rd
May 2025

Starhotels
Business Palace



GISEA/OEG PRESIDENTS

Giovanni LAPADULA
President of GISEA
(Gruppo Italiano di Studio sulla Early Arthritis)
Bari (Italy)

Gianfranco FERRACCIOLI
President of OEG
(Osservatorio Epidemiologico GISEA)
Roma (Italy)

SCIENTIFIC ORGANIZERS

Roberto CAPORALI
Milano (Italy)

Florenzo IANNONE
Bari (Italy)

SCIENTIFIC COMMITTEE

Fabiola ATZENI
Messina (Italy)

Roberto CAPORALI
Milano (Italy)

Fabrizio CONTI
Roma (Italy)

Ennio Giulio FAVALLI
Milano (Italy)

Elisa GREMESE
Milano (Italy)

Florenzo IANNONE
Bari (Italy)

Marco SEBASTIANI
Parma (Italy)

FACULTY

Stefano Alivernini
Roma (Italy)

Fabiola Atzeni
Messina (Italy)

Chiara Bazzani
Brescia (Italy)

Serena Bugatti
Pavia (Italy)

Alessandra Burgio
Messina (Italy)

Fabio Cacciapaglia
Bari (Italy)

Francesco Paolo Cantatore
Foggia (Italy)

Roberto Caporali
Milano (Italy)

Alberto Cauli
Cagliari (Italy)

Massimiliano Cazzato
Pisa (Italy)

Eleonora Celletti
Chieti (Italy)

Maria Sole Chimenti
Roma (Italy)

Gilberto Cincinelli
Milano (Italy)

Fabrizio Conti
Roma (Italy)

Ada Corrado
Foggia (Italy)

Lorenzo Dagna
Milano (Italy)

Cosimo De Bari
Edinburgh (UK)

Nicoletta Del Papa
Milano (Italy)

Ennio Giulio Favalli
Milano (Italy)

Gianfranco Ferraccioli
Roma (Italy)

Valerio Fiorilli
Roma (Italy)

Marco Fornaro
Bari (Italy)

Rosario Foti
Catania (Italy)

Maria Gerosa
Milano (Italy)

Marcello Govoni
Ferrara (Italy)

Elisa Gremese
Milano (Italy)

Serena Guiducci
Firenze (Italy)

Florenzo Iannone
Bari (Italy)

Giovanni Lapadula
Bari (Italy)

Giuseppe Lopalco
Bari (Italy)

Ennio Lubrano
Campobasso (Italy)

Andreina Manfredi
Modena (Italy)

Marco Matucci Cerinic
Milano (Italy)

Sara Monti
Milano (Italy)

Benedetta Monosi
Roma (Italy)

Maria Morrone
Bari (Italy)

Lykke Midtboll Ornbjerg
Copenhagen (Denmark)

Roberto Padoan
Padova (Italy)

Ilenia Pantano
Napoli (Italy)

Simone Parisi
Torino (Italy)

Simone Perniola
Bari (Italy)

Costantino Pitzalis
London (UK) Milano (Italy)

Roberta Ramonda
Padova (Italy)

Leonardo Santo
Barletta (Italy)

Piercarlo Sarzi Puttini
Milano (Italy)

Rossana Scrivo
Roma (Italy)

Marco Sebastiani
Parma (Italy)

Angelo Semeraro
Martina Franca (Italy)

Francesca Romana Spinelli
Roma (Italy)

Nicola Sverzellati
Parma (Italy)

Riccardo Terribili
Siena (Italy)

SCIENTIFIC ECM PROGRAM

SPONSORED LECTURE

SUMMARY TABLE - WEDNESDAY 21st MAY

14.30 – 15.00	Congress opening
15.00 – 15.30	Lecture: New drugs for the treatment of autoimmune rheumatological diseases
15.30 – 17.00	SESSION I Treatment of systemic vasculitis: what's new
17.00 – 17.30	Sponsored Lecture - NO ECM ELI LILLY iXperience in PsA: nuovi insights dalla real life con ixekizumab
17.30 – 18.00	Sponsored Lecture - NO ECM ALFASIGMA Filgotinib in RA: from Clinical Trials to Real-Life Experience

SUMMARY TABLE - THURSDAY 22nd MAY

09.00 – 10.30	SESSION II News on the customised approach in the management of spondyloarthritis
11.00 – 12.30	SESSION III Bone and surroundings
13.30 – 14.45	SESSION IV Rheumatoid Arthritis: the multiple faces of precision medicine

SCIENTIFIC ECM PROGRAM

SPONSORED LECTURE

SUMMARY TABLE - THURSDAY 22nd MAY

14.45 – 15.15	Sponsored Lecture - NO ECM NOVARTIS Secukinumab in PsA: dalla RWE al Patient profiling
15.45 – 16.30	Sponsored Lecture - NO ECM ABBVIE L'evoluzione di upadacitinib nelle indicazioni reumatologiche: nuove prospettive cliniche
16.30 – 17.00	Sponsored Lecture - NO ECM JOHNSON&JOHNSON Guselkumab nella gestione multi-dominio dell'artrite psoriasica: nuove evidenze dalla real life
17.00 – 17.30	Sponsored Lecture - NO ECM BOEHRINGER INGELHEIM Interstitial Lung Disease in Rheumatoid Arthritis: a Multidisciplinary Approach between Rheumatologist and Radiologist

SUMMARY TABLE - FRIDAY 23rd MAY

09.00 – 10.00	V SESSION Systemic lupus erythematosus
10.00 – 11.00	VI SESSION GISEA registry from an international prospective. The role of real world data
11.30 – 12.00	Sponsored Lecture - NO ECM ELI LILLY Baricitinib: vantaggi e opportunità della modulazione citochinica
12.00 – 12.20	Sponsored Lecture - NO ECM UCB Certolizumab Pegol: Tailoring Treatment for RA Patients with High RF Titers
12.20 – 13.00	Sponsored Lecture - NO ECM UCB From clinical trials to clinical practice: what perspectives from the dual inhibition of IL17A and IL17F?
14.00 – 17.00	SESSIONE GISEA REGISTRY Safety and drug retention of bDMARDS and tsDMARDS

EDUCATIONAL AIMS

The landscape of rheumatology is undergoing a profound transformation with the emergence of precision medicine and personalized medicine approaches. While these terms are often used interchangeably, they represent distinct paradigms that offer unique opportunities and challenges in managing rheumatic diseases. This congress aims to explore and clarify these approaches while addressing their practical implementation in rheumatology care. Rheumatic diseases represent a complex spectrum of disorders characterized by their heterogeneous nature, variable progression patterns and diverse treatment responses. Traditional “one-size-fits-all” treatment approaches have shown limited success in managing these conditions effectively, leading to the emergence of more targeted strategies. The field faces several critical challenges as high variability in disease manifestations and progression, unpredictable treatment responses, complex interactions between genetic, environmental, and lifestyle factors, limited understanding of disease subtypes and endotypes, growing array of therapeutic options with varying effectiveness across patient subgroups Precision Medicine vs Personalized Medicine?

This congress will explore the fundamental differences between these approaches: Precision Medicine is focused on:

- stratifying patients into subgroups based on biomarkers, genetics, and molecular pathways
- use of advanced technologies and “-omics” approaches
- identification of specific disease mechanisms and targeted treatments

Personalized Medicine is based on:

- the individual patient's broader context, including lifestyle, preferences, and social factors
- incorporation of patient-reported outcomes and quality of life measures
- sharing decision-making and patient engagement

During the congress will be discussed:

1. Diagnostic approaches as novel biomarker discovery, integration of multi-omics data, artificial intelligence
2. Treatment Strategies as biomarker-guided therapy selection, prediction models for treatment response, patient-specific dosing approaches, risk stratification methods, decision support tools, integration of real-world evidence

Through interactive sessions, expert presentations, and collaborative discussions, this congress will address the crucial question of how to effectively combine precision and personalized medicine approaches to optimize the management of rheumatic diseases while maintaining practical feasibility in real-world clinical settings.

LOCATION

The Gisea/OEG International Symposium 2025 will be held in
Starhotels Business Palace - Via Privata Pietro Gaggia, 3 - 20139 Milano

ECM PROGRAM

WEDNESDAY 21st MAY

MEETING ROOM VISCONTEA

14.30 – 15.00

Congress Opening

Giovanni Lapadula, Gianfranco Ferraccioli

Saluti Istituzionali

CHAIRMEN: *Marco Matucci Cerinic, Piercarlo Sarzi Puttini*

15.00 – 15.30

Lecture:

**New drugs for the treatment
of autoimmune rheumatological diseases**
Roberto Caporali

SESSION I

Treatment of systemic vasculitis: what's new

CHAIRMEN:

Chiara Bazzani, Roberta Ramonda, Marco Sebastiani

15.30 – 15.50

**Towards personalized medicine in EGPA:
new therapeutic options for different disease phenotypes**
Sara Monti

15.50 – 16.10

**The heterogeneous lung involvement of GPA and MPA:
from vasculitis to lung fibrosis through old and
new therapeutic options**
Andreina Manfredi

16.10 – 16.30

**Large vessel vasculitis: is a new era for treatment
and monitoring coming? IL6, JAK Inhibitors and more:
a starting point for a personalized medicine**
Roberto Padoan

16.30 – 17.00

Discussion

ECM PROGRAM

THURSDAY 22nd MAY
MEETING ROOM VISCONTEA

SESSION II **News on the customised approach in the management of spondyloarthritis**

CHAIRMEN:
Massimiliano Cazzato, Ennio Giulio Favalli

- | | |
|---------------|--|
| 09.00 – 09.20 | Axial involvement in SpAs: different treatment strategies?
<i>Ennio Lubrano</i> |
| 09.20 – 09.40 | Targeting IL17, IL23 or Janus Kineses in clinical practice:
is precision medicine in the treatment of Psoriatic Arthritis
really achievable?
<i>Maria Sole Chimenti</i> |
| 09.40 – 10.00 | When the management of Spondyloarthritis becomes
complex: the definition and the treatment of D2T axial SpA
<i>Alberto Cauli</i> |
| 10.00 – 10.30 | Discussion |
| 10.30 – 11.00 | Coffee break |

ECM PROGRAM

THURSDAY 22nd MAY
MEETING ROOM VISCONTEA

SESSION III **Bone and surroundings**

CHAIRMEN:
Francesco Paolo Cantatore, Fabrizio Conti, Angelo Semeraro

- | | |
|---------------|---|
| 11.00 – 11.20 | Osteoarthritis: from pathogenesis to treatment
<i>Cosimo De Bari</i> |
| 11.20 – 11.40 | Osteoporosis: the advantages of sequential therapy:
anabolics then anti resorptives or viceversa. When and how
<i>Riccardo Terribili</i> |
| 11.40 – 12.00 | Update on crystal-induced arthropathies:
clarity on pathogenesis and clinical aspects, uncertainties
about diagnosis and therapy
<i>Rossana Scrivo</i> |
| 12.00 – 12.30 | Discussion |
| 12.30 – 13.30 | Lunch |

ECM PROGRAM

THURSDAY 22nd MAY
MEETING ROOM VISCONTEA

SESSION IV **Rheumatoid Arthritis:** **the multiple faces of precision medicine**

CHAIRMEN: *Rosario Foti, Elisa Gremese, Leonardo Santo*

- | | |
|---------------|--|
| 13.30 – 13.50 | Seronegative Rheumatoid Arthritis:
a growing entity and a skein to unravel
<i>Serena Bugatti</i> |
| 13.50 – 14.10 | Is it possible to trace a disease trajectory from the onset
of Rheumatoid Arthritis? If yes, should we target molecules,
T cells, B cells, or myeloid cells?
<i>Simone Perniola</i> |
| 14.10 – 14.30 | Precision medicine in D2T RA
<i>Costantino Pitzalis</i> |
| 14.30 – 14.45 | Discussion |

ECM PROGRAM

FRIDAY 23rd MAY
MEETING ROOM VISCONTEA

SESSION V **Systemic Lupus Erythematosus**

CHAIRMEN: *Fabiola Atzeni, Maria Gerosa*

- | | |
|---------------|---|
| 09.00 – 09.20 | From pathogenesis to the new treatment strategies
for non-renal SLE
<i>Fabrizio Conti</i> |
| 09.20 – 09.40 | The new era in the treatment of renal SLE
<i>Marcello Govoni</i> |
| 09.40 – 10.00 | Discussion |

SESSION VI **GISEA registry from an international prospective. The role of real world data**

CHAIRMEN: *Roberto Caporali, Ada Corrado*

- | | |
|---------------|--|
| 10.00 – 10.20 | JAK-POT study
<i>Florenzo Iannone</i> |
| 10.20 – 10.40 | EURO-SPA
<i>Lykke Midtbøll Ørnbjerg</i> |
| 10.40 – 11.00 | Discussion |
| 11.00 – 11.30 | Coffee Break |

SPONSORED LECTURES NO ECM

WEDNESDAY 21st MAY
MEETING ROOM VISCONTEA

- 17.00 – 17.30** **Sponsor Lecture - No ECM Eli Lilly**
iXperience in PsA: nuovi insights dalla real life
con ixekizumab
SPEAKER: *Simone Parisi*
CHAIRMEN: *Eleonora Celletti, Giuseppe Lopalco*
- 17.30 – 18.00** **Sponsor Lecture - No ECM Alfasigma**
Filgotinib in RA: From Clinical Trials to Real-Life Experience
SPEAKER: *Serena Bugatti*
CHAIRMEN: *Roberto Caporali, Rosario Foti*
- 18.00 – 19.00** **Assemblea dei Centri GISEA**

SPONSORED LECTURES NO ECM

THURSDAY 22nd MAY
MEETING ROOM VISCONTEA

- 14.45 – 15.15** **Sponsor Lecture - No ECM Novartis**
Secukinumab in PsA: dalla RWE al Patient profiling
SPEAKER: *Fabrizio Conti*
CHAIRMEN: *Alberto Cauli, Ennio Lubrano*
- 15.15 – 15.45** **Coffee break**
- 15.45 – 16.30** **Sponsor Lecture - No ECM Abbvie**
L'evoluzione di upadacitinib nelle
indicazioni reumatologiche: nuove prospettive cliniche
SPEAKERS: *Lorenzo Dagna, Giuseppe Lopalco*
CHAIRMEN: *Roberto Caporali, Florenzo Iannone*
- 16.30 – 17.00** **Sponsor Lecture - No ECM Johnson&Johnson**
Guselkumab nella gestione multi-dominio
dell'artrite psoriasica: nuove evidenze dalla real life
SPEAKER: *Ilenia Pantano*
CHAIRMEN: *Roberto Caporali, Elisa Gremese*
- 17.00 – 17.30** **Sponsor Lecture - No ECM Boehringer Ingelheim**
Interstitial Lung Disease in Rheumatoid Arthritis:
a Multidisciplinary Approach between Rheumatologist
and Radiologist
SPEAKERS: *Marco Sebastiani, Nicola Sverzellati*
CHAIRMEN: *Nicoletta Del Papa, Florenzo Iannone*

SPONSORED LECTURES NO ECM

FRIDAY 23rd MAY

MEETING ROOM VISCONTEA

- 11.30 – 12.00** **Sponsor Lecture - No ECM Eli Lilly**
Baricitinib: vantaggi e opportunità della modulazione citochinica
SPEAKER: *Fabio Cacciapaglia*
CHAIRMAN: *Serena Guiducci*
- 12.00 – 12.20** **Sponsor Lecture - No ECM UCB**
Certolizumab Pegol: Tailoring Treatment for RA Patients with High RF Titers
SPEAKER: *Francesca Romana Spinelli*
CHAIRMAN: *Marcello Govoni*
- 12.20 – 13.00** **Sponsor Lecture - No ECM UCB**
From clinical trials to clinical practice: what perspectives from the dual inhibition of IL17A and IL17F?
SPEAKERS: *Ennio Giulio Favalli, Giuseppe Lopalco*
CHAIRMAN: *Ennio Lubrano*
- 13.00 – 14.00** **Lunch**



SESSION NO ECM

FRIDAY 23rd MAY
MEETING ROOM VISCONTEA

Sessione GISEA REGISTRY Safety and drug retention of bDMARDs and tsDMARDs

CHAIRMEN: Roberto Caporali, Florenzo Iannone

14.00 – 15.00

GISEA: one year in Review

1. Chimenti MS, et al. Effectiveness of ixekizumab over 24 months in different clinical scenarios in Psoriatic Arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry. Clin Exp Rheumatol. 2024 Jul 24. doi: 10.55563/clinexprheumatol/udiit0. Epub ahead of print. PMID: 39051160.
2. Fornaro M, et al. from the GISEA registry. Effectiveness and safety of filgotinib in Rheumatoid Arthritis patients: data from the GISEA registry. mClin Exp Rheumatol. 2024 May;42(5):1043-1050. doi: 10.55563/clinexprheumatol/b40rv4. Epub 2024 Apr 17. PMID: 38634362.
3. Manfredi A, et al. Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly Rheumatoid Arthritis patients: data from GISEA registry. Front Med (Lausanne). 2024 Mar 11;11:1349533. doi: 10.3389/fmed.2024.1349533. PMID: 38529117; PMCID: PMC10961352.
4. Scagnellato L, et al. GISEA Study Group. Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs. Clin Exp Rheumatol. 2024 Jan;42(1):104-114. doi: 10.55563/clinexprheumatol/q38lu0. Epub 2023 Aug 30. PMID: 37650298.
5. Real-world persistence and clinical effectiveness of secukinumab for Psoriatic Arthritis: Observational analysis of the Italian GISEA Registry - Lopalco G, (submitted).
6. Nintedanib in Rheumatoid Arthritis related interstitial lung disease: real-world safety profile and risk of side effects and discontinuation. Sebastiani M, et al. (submitted)

SESSION NO ECM

FRIDAY 23rd MAY
MEETING ROOM VISCONTEA

7. Italian multicenter real-world study on twelve months effectiveness, safety, and retention rate of guselkumab in Psoriatic Arthritis patients. Atzeni F, (Submitted)
8. Targeting Axial and Peripheal Involvement in Psoriatic Arthritis: Real-World Effectiveness of Upadacitinib for Disease Control and Patient- Centered Outcome. Celletti E, (Submitted)

15.00 – 16.10

GISEA Registry: What's cooking in the pot?

1. Cycling tra JAK inibitori nel trattamento delle malattie reumatiche (JAK-inhibitors cycling in rheumatic diseases – JOY)
Francesca Romana Spinelli
2. GISEA Synovial Tissue study group
Stefano Alivernini
3. Pharmacological interventions leading to a persistent escape from the D2T-RA status
Gilberto Cincinelli, Ennio Giulio Favalli
4. Prevalence of difficult to treat (D2T) among elderly rheumatoid arthritis (RA) patients
Andreina Manfredi
5. Profilo di effectiveness dei b/tsDMARDs nei pazienti difficult-to-treat con artrite reumatoide
Marco Fornaro
6. Treatment response according to gender in PsA
Elisa Gremese, Francesca Romana Spinelli
7. Incidence of all malignancies in RA patients treated with JAKi compared to those treated with bDMARDs (excluding TNF inhibitors): data from GISEA registry.
(approvato ottobre 2024)
Fabiola Atzeni

16.10 – 17.00

GISEA registry: where are we now?

Alessandra Burgio, Valerio Fiorilli, Benedetta Monosi, Maria Morrone
Conclusions & next steps

LINKS

BEST FOLLOWER 2025

 A prize will be awarded to the medical postgraduate or young doctor showing the most dedicated participation on the event's social networks 

 Visit our website www.gisea.eu

 Subscribe to Gruppo di Reumatologia • Registri GISEA/OEG, visit our showcase page GISEA/OEG - Gruppo Italiano di Studio Early Arthritis

 Visit our Facebook page Gruppo Italiano Studio Early Arthritis - Gisea/Org

 Follow @Gisea_Oeg or search #gisea2025 to join the discussion

REGISTRATION FEE

The registration fee is € 600,00 + 22% VAT (€ 732,00 VAT included), payable by bank transfer to the following account: Formedica Srl (IBAN CODE: IT 42 0326816000 052668696720; SWIFT CODE: SELBIT2BXXX). Please send a copy of the bank transfer (by fax: +39.0832.304994 or email: ecm@formedica.it) to the Organizing Secretariat.

ECM

Continuing Medical Education (ECM)

The GISEA International Symposium 2025 will be included in the ECM programme of the Italian Ministry of Health as an educational and residential activity (157- 446292) for n. 130 participants (disciplines: Rheumatology, Internal Medicine, Allergology and Clinical Immunology, Pneumology, Orthopedics and Traumatology).

The Symposium has obtained no. 5,6 Ecm credits.

Credit assignment depends on the participation to the whole ECM training program, as detailed below:

*Wednesday 21st May: from 2:30 PM to 5:00 PM

*Thursday 22nd May: from 09:00 AM to 10:30 AM and from 11:00 AM to 12:30 PM
and from 01:30 PM to 02:45 PM

*Friday 23rd May: from 09:00 AM to 11:00 AM

Credit attribution depends on actual participation of at the least 90% of the ECM program.

Participants must fill all requirements of the ECM registration form present on the DEEP ECM App.

Data fields on the form will include personal data such as Name, Surname, VAT Numer (Codice Fiscale), Address, Profession, Specialty and are required by the ECM commission in order to attribute the credits correctly. ECM quizzes will be available on the DEEP ECM App by the evening of May 23rd and will be accessible for 3 days. Following ECM rules, participants only have one attempt at passing the test.

A participation certificate will be given to all participants at the end of the Symposium.

**OBIETTIVO FORMATIVO: DOCUMENTAZIONE CLINICA. PERCORSI CLINICO-ASSISTENZIALI
DIAGNOSTICI E RIABILITATIVI, PROFILI DI ASSISTENZA-PROFILI DI CURA (3).**

SPONSORSHIP With the non conditional support of:

PLATINUM



Inspired by patients.
Driven by science.

GOLDEN





PARTNERSHIP



Segreteria Organizzativa
Provider n. 157

FORMEDICA
Scientific Learning

SEDE LECCE

Viale Japigia 18 • 73100 Lecce

SEDE MILANO

Via Privata della Passarella 4
Piano 2 Zona 1 • 20122 Milano

Tel/Fax: +39.0832.304994
Mobile +39.375.6589214
ecm@formedica.it
www.formedica.it